Circulating Tumor Cells in Patients with Breast Cancer: Monitoring Chemotherapy Success

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10287019" target="_blank" >RIV/00216208:11110/14:10287019 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/14:43908598 RIV/00064173:_____/14:#0000404 RIV/00064165:_____/14:10287019

Výsledek na webu

<a href="http://iv.iiarjournals.org/content/28/4/605.short" target="_blank" >http://iv.iiarjournals.org/content/28/4/605.short</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Circulating Tumor Cells in Patients with Breast Cancer: Monitoring Chemotherapy Success

Popis výsledku v původním jazyce

Circulating tumor cells (CTCs) are an independent prognostic factor for patients with metastatic breast cancer (MBC). However, the role of CTCs in early breast cancer management is not yet clearly defined. The aim of this study was to assess the CTC-positivity rate in patients undergoing chemotherapy depending on breast cancer stage in the adjuvant and neoadjuvant setting. We evaluated the ability to confirm therapy response by CTC analysis. CTCs isolated from blood by means of immunomagnetic separationwere further characterized by means of reverse transcriptase polymerase chain reaction (RT-PCR) for epithelial cell adhesion molecule (EPCAM), mucin 1 (MUC1) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (HER2) transcripts with theAdnaTest (TM). This prospective study included 179 patients; altogether 419 blood samples were evaluated. Patients with primary tumors were divided into neoadjuvant (n=38), and adjuvant (n=100) groups. Forty-one patients with MBC were ev

Název v anglickém jazyce

Circulating Tumor Cells in Patients with Breast Cancer: Monitoring Chemotherapy Success

Popis výsledku anglicky

Circulating tumor cells (CTCs) are an independent prognostic factor for patients with metastatic breast cancer (MBC). However, the role of CTCs in early breast cancer management is not yet clearly defined. The aim of this study was to assess the CTC-positivity rate in patients undergoing chemotherapy depending on breast cancer stage in the adjuvant and neoadjuvant setting. We evaluated the ability to confirm therapy response by CTC analysis. CTCs isolated from blood by means of immunomagnetic separationwere further characterized by means of reverse transcriptase polymerase chain reaction (RT-PCR) for epithelial cell adhesion molecule (EPCAM), mucin 1 (MUC1) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (HER2) transcripts with theAdnaTest (TM). This prospective study included 179 patients; altogether 419 blood samples were evaluated. Patients with primary tumors were divided into neoadjuvant (n=38), and adjuvant (n=100) groups. Forty-one patients with MBC were ev

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT14441" target="_blank" >NT14441: Cirkulující a diseminované nádorové buňky v diagnostice a léčbě pokročilých stadií karcinomu ovaria</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

In Vivo

ISSN

0258-851X

e-ISSN

—

Svazek periodika

28

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

10

Strana od-do

605-614

Kód UT WoS článku

000338777500026

EID výsledku v databázi Scopus

—